Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

We are targeting to start multiple clinical trials in the second half of calendar year 2025 with a novel and proprietary long-acting MC4R peptide ... dual agonist tirzepatide, expected in the ...

(HealthDay News) — Websites that sell compounded glucagon-like peptide-1 receptor agonists ... according to a research letter published online in JAMA Health Forum. Ashwin K.

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

Recent research has focused on innovative ... is the introduction of medications like tirzepatide and semaglutide, both of which are glucagon-like peptide-1 (GLP-1) receptor agonists.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and Drug Administration approval, ...

Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide ... Research has shown that Zepbound’s active ingredient, tirzepatide, is ...